Serum’s Covishield and Bharat Biotech’s Covaxin are examples of atmanirbhar (self-reliance) but have an element of non-Indian science — and at least to me that is fine, says Dr. Gagandeep Kang. Though Covaxin uses inactivated virus, neutralising antibodies against the spike protein are critical for reinfection. So if Covaxin is based on an old viral […]
I would not take Covaxin without efficacy data: Gagandeep Kang — Science Chronicle
The Centers for Disease Control and Prevention said at present it looks like anaphylaxis cases are occurring at a rate of about 5.5 per 1 million vaccine doses given, though the agency cautioned that figure may change as the vaccination effort continues.
The allergic reactions do not change CDC’s recommendations on who can be vaccinated against Covid-19, with senior officials stressing that the risk of severe illness and death from the disease still outweighs the risk of developing anaphylaxis after vaccination.
CDC reports more allergic reactions to Covid-19 vaccines, but cases remain few — https://www.statnews.com/2021/01/06/cdc-reports-more-allergic-reactions-to-covid-19-vaccines-but-cases-remain-few/?utm_campaign=rss
Get jabbed.
Some vaccine experts, though, said they are not surprised by the speed of vaccine distribution so far. “It had to go this way,” Paul Offit, a professor of pediatrics at Children’s Hospital of Philadelphia, told STAT. “We had to trip and fall and stumble and figure this out.”
Claire Hannan, executive director of the Association of Immunization Managers, said some of the gap between doses administered and delivered is likely due to a program run by CVS and Walgreens to vaccinate those in nursing homes. States participating in the program have to set aside 50% of their doses, which Hannan said could account for a share of the difference between doses shipped and doses administered nationally.
“I don’t think it’s bad,” she said of the pace of distribution so far. “I think it was always going to be like this. And I think that this is actually the easy part.”
Frustration over vaccine rollout builds, as new variant reported in U.S. for first time — https://www.statnews.com/2020/12/29/public-health-experts-grow-frustrated-with-pace-of-covid-19-vaccine-rollout/?utm_campaign=rss
We are definitely so screwed.
The coronavirus vaccine is finally a real thing and millions of people have already received it. While the rollout has the world cheering, researchers from Virginia Commonwealth University finds many Americans aren’t exactly chomping at the bit to be the first in line for the vaccine under an emergency use authorization. Their survey reveals 53.1 percent are definitely, likely, or somewhat unwilling to get the shot under emergency use conditions.
Over half of U.S. adults ‘unlikely’ to get COVID vaccine under emergency use authorization — https://www.studyfinds.org/half-adults-unlikely-to-get-covid-vaccine/
Journal Reference
Published:November 19, 2020 DOI:https://doi.org/10.1016/j.ajic.2020.11.018
We are so screwed.
In animal tests, NVX-CoV2373 vaccination produced antibodies that blocked the coronavirus spike protein from binding to the cell surface receptors targeted by the virus, preventing viral infection. In results(link is external) of a Phase 1 clinical trial published in the New England Journal of Medicine, NVX-CoV2373 was generally well-tolerated and elicited higher levels of antibodies than those seen in blood samples drawn from people who had recovered from clinically significant COVID-19. NVX-CoV2373 also is being evaluated in a Phase 2b trial in South Africa, now fully enrolled with 4,422 volunteers, and data from a Phase 1/2 continuation trial in the United States and Australia is expected as early as first quarter 2021. Novavax also recently completed enrollment of more than 15,000 volunteers in a Phase 3 trial of the candidate vaccine in the United Kingdom, which is also testing two injections of 5 mcg of protein and 50 mcg of Matrix-M adjuvant administered 21 days apart.
Phase 3 trial of Novavax investigational COVID-19 vaccine opens — https://www.nih.gov/news-events/news-releases/phase-3-trial-novavax-investigational-covid-19-vaccine-opens
Residents are the lowest-ranking doctors in a hospital. Stanford Medicine has about 1,300 across all disciplines. Only seven made the priority vaccination list, despite the fact that this week, residents were asked to volunteer for ICU coverage in anticipation of a surge in COVID-19 cases.
“Residents are patient-facing, we’re the ones who have been asked to intubate, yet some attendings who have been face-timing us from home are being vaccinated before us,” said Dr. Sarah Johnson, a third-year OB-GYN resident who has delivered babies from COVID-positive patients during the pandemic. “This is the final straw to say, ‘We don’t actually care about you.’”
Only Seven of Stanford’s First 5,000 Vaccines Were Designated for Medical Residents – https://www.propublica.org/article/only-seven-of-stanfords-first-5-000-vaccines-were-designated-for-medical-residents
Stanford Medicine demonstrates how much they care about their residents.
Here’s an interesting breakdown of lessons learned.
In its earliest attempts at explaining the problem, Stanford’s administrators laid blame with the algorithm. Despite best intentions, they explained, the algorithm had made a mistake that the humans had to answer for.
This is a bit like blaming the hammer for missing the nail.
3 lessons from Stanford’s Covid-19 vaccine algorithm debacle — https://www.statnews.com/2020/12/21/stanford-covid19-vaccine-algorithm/
Operation Warp Speed also experienced some hiccups.
“It looked very good on paper,” Perna said. “Paper plans are very good. Execution is where we learn, and we adapted accordingly.”
‘I failed’: Operation Warp Speed leader takes responsibility for Covid-19 vaccine distribution confusion — https://www.statnews.com/2020/12/19/operation-warp-speed-leader-takes-sole-responsibility-for-covid-19-vaccine-distribution-confusion/?utm_campaign=rss
Remember “Everybody has a plan until they get punched in the mouth”
The most common side effects are injection site pain, fatigue, headache, muscle pain, and joint pain. Some people in the clinical trials have reported fever. Side effects are more common after the second dose; younger adults, who have more robust immune systems, reported more side effects than older adults.
To be clear: These side effects are a sign of an immune system kicking into gear. They do not signal that the vaccine is unsafe. To date there are no serious, long-term side effects associated with receipt of these vaccines, which will be closely monitored as their use expands.
A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines — https://www.statnews.com/2020/12/19/a-side-by-side-comparison-of-the-pfizer-biontech-and-moderna-vaccines/?utm_campaign=rss
Post and link for informational purposes only. I will not waste my time trying to convince people that a virus doesn’t care about your gender, age, sexuality, religion, skin color, politics, net worth, personal freedoms, dietary preferences, or anything else.
A virus merely wants a host organism to infect.
As one who has suffered the severest of allergic reactions, anaphylaxis, on several occasions after nut ingestion, I was quite worried when I heard that the British FDA-equivalent had announced that “any person with a history of anaphylaxis to a vaccine, medicine or food should not receive the Pfizer BioNTech vaccine.” The UK began vaccinating…
Severe Allergic or Anaphylactic Food Reactions and the COVID-19 Vaccine — The Skeptical Cardiologist
Thank you Dr. Pearson.
They examined the records of nearly 300,000 adults in the U.S. who had an initial atherosclerotic cardiovascular disease event between 2007 and 2016. These were divided into three groups: coronary heart disease, ischemic stroke or transient ischemic attack, or peripheral artery disease.
When people left the hospital or emergency department in 2007 following a first diagnosis in one of these categories, about half began taking statins within 30 days. By 2016, statin use increased to approximately 60%.
“Based on the guidelines, we hoped to see a much higher uptake among this entire group,” says Dr. Noseworthy. “Statin intolerance was only noted for 4%-5% of the patients, which means as many as 35% of patients are not receiving treatment according to the guidelines.”
Mayo Clinic. “Statins can save lives; are they being used?.” ScienceDaily. http://www.sciencedaily.com/releases/2020/12/201201144030.htm (accessed December 2, 2020) — https://www.sciencedaily.com/releases/2020/12/201201144030.htm
Journal Reference:
Xiaoxi Yao, Nilay D. Shah, Bernard J. Gersh, Francisco Lopez-Jimenez, Peter A. Noseworthy. Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016. JAMA Network Open, 2020; 3 (11): e2025505 DOI: 10.1001/jamanetworkopen.2020.25505
lifeunderwriter.net 
You must be logged in to post a comment.